The PD‐1/PD‐L1 axis has become a focal point in TNBC immunotherapy.[182] PD‐1 is a receptor expressed on T cells that, upon binding to its ligand PD‐L1 on tumor cells, suppresses T‐cell function and facilitates immune evasion. Here, CD274 is linked to neoplasm.